{"brief_title": "A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)", "brief_summary": "This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech growth hormone (GH) preparations to treat children with CRI in the United States.", "condition": "End-Stage Renal Disease", "study_pop": "\n      ", "sampling_method": "Non-Probability Sample", "criteria": "Inclusion Criteria: - Children diagnosed with CRI or ESRD and treated with a Genentech GH preparation on or after 1 January 2001 - CRI documented using the Schwartz formula indicates a calculated creatinine clearance (CrCl) of <=75 mL/min/1.73 m^2 - Ability to keep follow up appointments throughout the study Exclusion Criteria: - Subjects receiving a non-Genentech GH preparation - Subjects with closed epiphyses - Subjects with active neoplasia - Current participation in another GH clinical study - Current participation in the core study", "gender": "All", "minimum_age": "N/A", "maximum_age": "17 Years", "healthy_volunteers": "No", "id": "NCT00097617.xml"}